Skip to main content
Top
Published in: BMC Infectious Diseases 1/2018

Open Access 01-12-2018 | Research article

Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach

Authors: Wail A. Hayajneh, Vincent J. Daniels, Cerise K. James, Muhammet Nabi Kanıbir, Matthew Pilsbury, Morgan Marks, Michelle G. Goveia, Elamin H. Elbasha, Erik Dasbach, Camilo J. Acosta

Published in: BMC Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Background

As the socioeconomic conditions in Jordan have improved over recent decades the disease and economic burden of Hepatitis A has increased. The purpose of this study is to assess the potential health and economic impact of a two-dose hepatitis A vaccine program covering one-year old children in Jordan.

Methods

We adapted an age-structured population model of hepatitis A transmission dynamics to project the epidemiologic and economic impact of vaccinating one-year old children for 50 years in Jordan. The epidemiologic model was calibrated using local data on hepatitis A in Jordan. These data included seroprevalence and incidence data from the Jordan Ministry of Health as well as hospitalization data from King Abdullah University Hospital in Irbid, Jordan. We assumed 90% of all children would be vaccinated with the two-dose regimen by two years of age. The economic evaluation adopted a societal perspective and measured benefits using the quality-adjusted life-year (QALY).

Results

The modeled vaccination program reduced the incidence of hepatitis A in Jordan by 99%, 50 years after its introduction. The model projected 4.26 million avoided hepatitis A infections, 1.42 million outpatient visits, 22,475 hospitalizations, 508 fulminant cases, 95 liver transplants, and 76 deaths over a 50 year time horizon. In addition, we found, over a 50 year time horizon, the vaccination program would gain 37,502 QALYs and save over $42.6 million in total costs. The vaccination program became cost-saving within 6 years of its introduction and was highly cost-effective during the first 5 years.

Conclusion

A vaccination program covering one-year old children is projected to be a cost-saving intervention that will significantly reduce the public health and economic burden of hepatitis A in Jordan.
Appendix
Available only for authorised users
Literature
1.
go back to reference Battikhi MN, Battikhi EG. The seroepidemiology of hepatitis a virus in Amman, Jordan. New Microbiol. 2004;27:215–20.PubMed Battikhi MN, Battikhi EG. The seroepidemiology of hepatitis a virus in Amman, Jordan. New Microbiol. 2004;27:215–20.PubMed
2.
go back to reference Toukan AU, Sharaiha ZK, Abu-el-Rob OA. The seroepidemiology of hepatitis a virus infection in Jordan. Trop Gastroenterol. 1988;9:76–9.PubMed Toukan AU, Sharaiha ZK, Abu-el-Rob OA. The seroepidemiology of hepatitis a virus infection in Jordan. Trop Gastroenterol. 1988;9:76–9.PubMed
3.
go back to reference Itani T, Jacobsen KH, Nguyen T, Wiktor SZ. A new method for imputing country-level estimates of hepatitis a virus endemicity levels in the eastern Mediterranean region. Vaccine. 2014;32:6067–74.CrossRef Itani T, Jacobsen KH, Nguyen T, Wiktor SZ. A new method for imputing country-level estimates of hepatitis a virus endemicity levels in the eastern Mediterranean region. Vaccine. 2014;32:6067–74.CrossRef
4.
go back to reference Jacobsen KH, Wiersma ST. Hepatitis a virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28:6653–7.CrossRef Jacobsen KH, Wiersma ST. Hepatitis a virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28:6653–7.CrossRef
5.
go back to reference Hayajneh WA, Balbeesi A, Faouri S. Hepatitis a virus age-specific sero-prevalence and risk factors among Jordanian children. J Med Virol. 2015;87:569–74.CrossRef Hayajneh WA, Balbeesi A, Faouri S. Hepatitis a virus age-specific sero-prevalence and risk factors among Jordanian children. J Med Virol. 2015;87:569–74.CrossRef
6.
go back to reference World Health Organization. WHO position paper on hepatitis a vaccines: June 2012 -recommendations. Vaccine. 2013;31:285–6.CrossRef World Health Organization. WHO position paper on hepatitis a vaccines: June 2012 -recommendations. Vaccine. 2013;31:285–6.CrossRef
7.
go back to reference Dhankhar P, Nwankwo C, Pillsbury M, Lauschke A, Goveia MG, Acosta CJ, et al. Public health impact and cost-effectiveness of hepatitis a vaccination in the United States: a disease transmission dynamic modeling approach. Value Heal. 2015;18:358–67.CrossRef Dhankhar P, Nwankwo C, Pillsbury M, Lauschke A, Goveia MG, Acosta CJ, et al. Public health impact and cost-effectiveness of hepatitis a vaccination in the United States: a disease transmission dynamic modeling approach. Value Heal. 2015;18:358–67.CrossRef
11.
go back to reference Jacobsen KH, Koopman JS. The effects of socioeconomic development on worldwide hepatis a virus seroprevalence patterns. Int J Epidemiol. 2005;34:600–9.CrossRef Jacobsen KH, Koopman JS. The effects of socioeconomic development on worldwide hepatis a virus seroprevalence patterns. Int J Epidemiol. 2005;34:600–9.CrossRef
12.
go back to reference Jacobsen KH. The global prevalence of hepatitis a virus infection and susceptibility: a systematic review. Geneva: World Heal Organ; 2009. Jacobsen KH. The global prevalence of hepatitis a virus infection and susceptibility: a systematic review. Geneva: World Heal Organ; 2009.
13.
go back to reference Directorate of Vital information Studies Preparation. Ministry of Health Annual Statistical Book 2014. Amman: Jordan Ministry of Health; 2015. Available from: http://www.moh.gov.jo Directorate of Vital information Studies Preparation. Ministry of Health Annual Statistical Book 2014. Amman: Jordan Ministry of Health; 2015. Available from: http://​www.​moh.​gov.​jo
14.
go back to reference Jiries A. Water resources in Jordan. Adv Water Supply Wastewater Treat A Road to Safer Soc Environ Springer. 2011:193–9. Jiries A. Water resources in Jordan. Adv Water Supply Wastewater Treat A Road to Safer Soc Environ Springer. 2011:193–9.
20.
go back to reference Armstrong GL, Bell BP. Hepatitis a virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics. 2002;109 Armstrong GL, Bell BP. Hepatitis a virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics. 2002;109
21.
go back to reference Rein DB, Hicks KA, Wirth KE, Billah K, Finelli L, Fiore AE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis a in the United States. Pediatrics. 2007;119:e12–21.CrossRef Rein DB, Hicks KA, Wirth KE, Billah K, Finelli L, Fiore AE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis a in the United States. Pediatrics. 2007;119:e12–21.CrossRef
22.
go back to reference Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, et al. A controlled trial of a formalin-inactivated hepatitis a vaccine in healthy children. N Engl J Med. 1992;327:453–7.CrossRef Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, et al. A controlled trial of a formalin-inactivated hepatitis a vaccine in healthy children. N Engl J Med. 1992;327:453–7.CrossRef
23.
go back to reference Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, Brown L, et al. Duration of protection from clinical hepatitis a disease after vaccination with VAQTA. J Med Virol. 1996;49:235–41.CrossRef Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, Brown L, et al. Duration of protection from clinical hepatitis a disease after vaccination with VAQTA. J Med Virol. 1996;49:235–41.CrossRef
25.
go back to reference Huda A, Newcomer R, Harrington C, Blegen MG, Keeffe EB. High rate of unemployment after liver transplantation: analysis of the united network for organ sharing database. Liver Transplant. 2012;18:89–99.CrossRef Huda A, Newcomer R, Harrington C, Blegen MG, Keeffe EB. High rate of unemployment after liver transplantation: analysis of the united network for organ sharing database. Liver Transplant. 2012;18:89–99.CrossRef
26.
go back to reference Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis a in Argentina: results of a dynamic health--economic analysis. J Gastroenterol. 2007;42:152–60.CrossRef Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis a in Argentina: results of a dynamic health--economic analysis. J Gastroenterol. 2007;42:152–60.CrossRef
28.
29.
go back to reference Luyten J, Marais C, Hens N, De Schrijver K, Beutels P. Imputing QALYs from single time point health state descriptions on the EQ-5D and the SF-6D: a comparison of methods for hepatitis a patients. Value Heal. 2011;14:282–90.CrossRef Luyten J, Marais C, Hens N, De Schrijver K, Beutels P. Imputing QALYs from single time point health state descriptions on the EQ-5D and the SF-6D: a comparison of methods for hepatitis a patients. Value Heal. 2011;14:282–90.CrossRef
30.
go back to reference Chong CAKY, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98:630–8.CrossRef Chong CAKY, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98:630–8.CrossRef
31.
go back to reference Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Mak. 2006;26:391–400.CrossRef Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Mak. 2006;26:391–400.CrossRef
32.
go back to reference Black WC. The CE plane a graphic representation of cost-effectiveness. Med Decis Mak. 1990;10:212–4.CrossRef Black WC. The CE plane a graphic representation of cost-effectiveness. Med Decis Mak. 1990;10:212–4.CrossRef
33.
go back to reference Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation a report of the ISPOR-SMDM modeling good research practices task force--7. Med Decis Mak. 2012;32:733–43.CrossRef Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation a report of the ISPOR-SMDM modeling good research practices task force--7. Med Decis Mak. 2012;32:733–43.CrossRef
34.
go back to reference Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis a in Israel following universal immunization of toddlers. JAMA. 2005;294:202–10.CrossRef Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis a in Israel following universal immunization of toddlers. JAMA. 2005;294:202–10.CrossRef
35.
go back to reference Cervio G, Trentadue J, D’Agostino D, Luque C, Giorgi M, Armoni J, et al. Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis a vaccination program. Hepat Med. 2011;3:99–106.CrossRef Cervio G, Trentadue J, D’Agostino D, Luque C, Giorgi M, Armoni J, et al. Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis a vaccination program. Hepat Med. 2011;3:99–106.CrossRef
36.
go back to reference Valenzuela MT, Jacobs RJ, Arteaga O, Navarrete MS, Meyerhoff AS, Innis BL. Cost-effectiveness of universal childhood hepatitis a vaccination in Chile. Vaccine. 2005;23:4110–9.CrossRef Valenzuela MT, Jacobs RJ, Arteaga O, Navarrete MS, Meyerhoff AS, Innis BL. Cost-effectiveness of universal childhood hepatitis a vaccination in Chile. Vaccine. 2005;23:4110–9.CrossRef
37.
go back to reference Sartori AMC, de Soárez PC, Novaes HMD, Amaku M, de Azevedo RS, Moreira RC, et al. Cost-effectiveness analysis of universal childhood hepatitis a vaccination in Brazil: regional analyses according to the endemic context. Vaccine. 2012;30:7489–97.CrossRef Sartori AMC, de Soárez PC, Novaes HMD, Amaku M, de Azevedo RS, Moreira RC, et al. Cost-effectiveness analysis of universal childhood hepatitis a vaccination in Brazil: regional analyses according to the endemic context. Vaccine. 2012;30:7489–97.CrossRef
38.
go back to reference Zahdi MR, Maluf Junior I, Maluf EMCP. Hepatitis a: the costs and benefits of the disease prevention by vaccine, Paranà, Brazil. Braz J Infect Dis. 2009;13:257–61.CrossRef Zahdi MR, Maluf Junior I, Maluf EMCP. Hepatitis a: the costs and benefits of the disease prevention by vaccine, Paranà, Brazil. Braz J Infect Dis. 2009;13:257–61.CrossRef
39.
go back to reference Van Effelterre TP, DeAntonio R, Cassidy A, Romano-Mazzotti L, Marano C. Model-based projections of the population-level impact of hepatitis a vaccination in Mexico. Hum Vaccin Immunother. 2012;8:1099–108.CrossRef Van Effelterre TP, DeAntonio R, Cassidy A, Romano-Mazzotti L, Marano C. Model-based projections of the population-level impact of hepatitis a vaccination in Mexico. Hum Vaccin Immunother. 2012;8:1099–108.CrossRef
40.
go back to reference Quezada A, Baron-Papillon F, Coudeville L, Maggi L. Universal vaccination of children against hepatitis a in Chile: a cost-effectiveness study. Rev Panam Salud Pública. 2008;23:303–12.CrossRef Quezada A, Baron-Papillon F, Coudeville L, Maggi L. Universal vaccination of children against hepatitis a in Chile: a cost-effectiveness study. Rev Panam Salud Pública. 2008;23:303–12.CrossRef
41.
go back to reference Anonychuk AM, Tricco AC, Bauch CT, Gilca V, Duval B, John-Baptiste A, et al. Cost-effectiveness analyses of hepatitis a vaccine. Pharmacoeconomics. 2008;26:17–32.CrossRef Anonychuk AM, Tricco AC, Bauch CT, Gilca V, Duval B, John-Baptiste A, et al. Cost-effectiveness analyses of hepatitis a vaccine. Pharmacoeconomics. 2008;26:17–32.CrossRef
42.
go back to reference Black S, Shinefield H, Hansen J, Lewis E, Su L, Coplan P. A post-licensure evaluation of the safety of inactivated hepatitis a vaccine (VAQTA®, Merck) in children and adults. Vaccine. 2004;22:766–72.CrossRef Black S, Shinefield H, Hansen J, Lewis E, Su L, Coplan P. A post-licensure evaluation of the safety of inactivated hepatitis a vaccine (VAQTA®, Merck) in children and adults. Vaccine. 2004;22:766–72.CrossRef
43.
go back to reference Niu MT, Salive M, Krueger C, Ellenberg SS. Two-year review of hepatitis a vaccine safety: data from the vaccine adverse event reporting system (VAERS). Clin Infect Dis. 1998;26(6):1475.CrossRef Niu MT, Salive M, Krueger C, Ellenberg SS. Two-year review of hepatitis a vaccine safety: data from the vaccine adverse event reporting system (VAERS). Clin Infect Dis. 1998;26(6):1475.CrossRef
44.
go back to reference Whitaker HJ, Farrington CP. Estimation of infections disease parameters from serological survey data: the impact of regular epidemics. Stat Med. 2004;23:2429–43.CrossRef Whitaker HJ, Farrington CP. Estimation of infections disease parameters from serological survey data: the impact of regular epidemics. Stat Med. 2004;23:2429–43.CrossRef
45.
go back to reference Linder N, Karetnyi Y, Gidony Y, Dagan R, Ohel G, Levin E, et al. Decline of hepatitis a antibodies during the first 7 months of life in full-term and preterm infants. Infection. 1999;27:128–31.CrossRef Linder N, Karetnyi Y, Gidony Y, Dagan R, Ohel G, Levin E, et al. Decline of hepatitis a antibodies during the first 7 months of life in full-term and preterm infants. Infection. 1999;27:128–31.CrossRef
46.
go back to reference Fiore AE, Wasley A, Bell BP. Prevention of hepatitis a through active or passive immunization: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2006;55:1–23.PubMed Fiore AE, Wasley A, Bell BP. Prevention of hepatitis a through active or passive immunization: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2006;55:1–23.PubMed
47.
go back to reference Leach CT. Hepatitis A in the United States. Pediatr Infect Dis J. 2004;23:551–2.CrossRef Leach CT. Hepatitis A in the United States. Pediatr Infect Dis J. 2004;23:551–2.CrossRef
48.
go back to reference Amariei R, Willms AR, Bauch CT. The United States and Canada as a coupled epidemiological system: an example from hepatitis a. BMC Infect Dis. 2008;8:23.CrossRef Amariei R, Willms AR, Bauch CT. The United States and Canada as a coupled epidemiological system: an example from hepatitis a. BMC Infect Dis. 2008;8:23.CrossRef
49.
go back to reference Martin A, Lemon SM, Hepatitis A. Virus: from discovery to vaccines. Hepatology. 2006;43:S164–72.CrossRef Martin A, Lemon SM, Hepatitis A. Virus: from discovery to vaccines. Hepatology. 2006;43:S164–72.CrossRef
50.
go back to reference Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999--2008. Am J Transplant. 2010;10:961–72.CrossRef Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999--2008. Am J Transplant. 2010;10:961–72.CrossRef
51.
go back to reference Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, et al. The cost of hepatitis a infections in American adolescents and adults in 1997. Hepatology. 2000;31:469–73.CrossRef Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, et al. The cost of hepatitis a infections in American adolescents and adults in 1997. Hepatology. 2000;31:469–73.CrossRef
52.
go back to reference Mryyan N. Demographics, labor force participation, and unemployment in Jordan. In: Assaad R, editor. Jordanian Labour Mark. New Millenn. Oxford: Oxford University Press; 2014. p. 39–63.CrossRef Mryyan N. Demographics, labor force participation, and unemployment in Jordan. In: Assaad R, editor. Jordanian Labour Mark. New Millenn. Oxford: Oxford University Press; 2014. p. 39–63.CrossRef
Metadata
Title
Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach
Authors
Wail A. Hayajneh
Vincent J. Daniels
Cerise K. James
Muhammet Nabi Kanıbir
Matthew Pilsbury
Morgan Marks
Michelle G. Goveia
Elamin H. Elbasha
Erik Dasbach
Camilo J. Acosta
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2018
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-018-3034-8

Other articles of this Issue 1/2018

BMC Infectious Diseases 1/2018 Go to the issue